Industry update from Biotech Showcase.
Almost 16min
AML and Glioblastoma are both orphan disease's.
Orphan gene (he throws in cell) therapies are 3.5 times more likely to be approved once entering phase 1 trials than average drugs included in BIO's global trends in R&D 2023 report.
- 48% higher success rate in phase 1 clinical trials.
- 65% higher success rate in phase 2 clinical trials.
- 30% higher success rate in phase 3 clinical trials.
I dare say our early positive data puts us even higher.
Industry update from Biotech Showcase. Almost 16minAML and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |